로봇 보조 경피적 관상동맥 중재술 시장 예측(2026-2032년)

The Robotic Assisted Percutaneous Coronary Intervention Market is projected to grow by USD 65.48 billion at a CAGR of 18.37% by 2032.

Robotic-Assisted PCI: Executive Overview

Robotic-assisted percutaneous coronary intervention (PCI) combines catheter-based coronary treatment with remote manipulation, specialized guidance, and enhanced procedural visualization. Its clinical rationale is to support precise device control, reduce operator radiation exposure, and improve ergonomics while preserving established PCI workflows. Adoption depends on clinical evidence, capital-equipment access, laboratory design, training, reimbursement, and institutional readiness.

How Robotic-Assisted PCI Is Reshaping Interventional Practice

The field is shifting from conventional manual operation toward digitally supported procedures that emphasize precision, repeatability, and operator protection. Integration with advanced imaging, physiologic assessment, navigation software, and structured data capture can strengthen procedural planning and quality assurance. The principal barriers remain workflow adaptation, equipment integration, credentialing, maintenance, and the need to demonstrate consistent patient and operational benefits across varied clinical settings.

Artificial Intelligence as a Cumulative Capability Layer

Artificial intelligence can augment robotic-assisted PCI through image interpretation, lesion and vessel assessment, procedural planning, device-path guidance, and post-procedure analytics. Its value is cumulative: connected imaging, robotics, and clinical records can support more standardized decision-making and identify process deviations. Safe deployment requires representative validation, clinician oversight, explainability, cybersecurity, interoperability, and clear accountability; AI should assist rather than replace interventional judgment.

Regional Insights Across the Global Landscape

North America is characterized by advanced cardiac-care infrastructure, high procedural specialization, and comparatively strong capacity for technology evaluation, while Latin America faces greater variation in funding, equipment access, and specialist distribution. Europe benefits from mature healthcare systems and coordinated clinical standards, although procurement and regulatory processes differ across countries. The Middle East is developing specialized tertiary-care capacity, and Africa remains highly heterogeneous, with access concentrated in major referral centers. Asia-Pacific combines sophisticated urban cardiac programs with substantial differences in affordability, workforce, and rural connectivity; training networks and adaptable deployment models are therefore important across the region.

Group-Level Priorities: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN countries require scalable training, referral coordination, and cost-conscious laboratory models suited to diverse health systems. BRICS members span advanced centers and major access gaps, making local evidence generation and tiered implementation especially relevant. The European Union emphasizes regulatory alignment, data governance, and cross-border clinical standards. G7 systems generally have strong research and specialist capacity but must address workflow efficiency and value assessment. GCC countries are investing in advanced tertiary care and can support centralized expertise, while NATO members may benefit from interoperable training, resilience planning, and shared standards for digitally enabled medical systems.

Country-Level Considerations for Adoption and Practice

Australia and Canada may prioritize regional access, workforce development, and integration with established cardiac networks. Brazil, Mexico, India, and Russia require approaches that account for pronounced differences between metropolitan referral centers and underserved areas. China, Japan, and South Korea have substantial technical capabilities and may focus on domestic evidence, advanced imaging integration, and specialist training. France, Germany, Italy, Spain, and the United Kingdom must align adoption with national procurement, reimbursement, clinical governance, and evidence requirements. The United States has extensive interventional expertise and technology infrastructure, with emphasis on clinical validation, operator training, safety, and documented workflow value.

Action Priorities for Industry and Healthcare Leaders

Leaders should begin with clearly defined clinical and operational use cases rather than technology-first deployment. Establish multidisciplinary governance spanning interventional cardiology, nursing, imaging, biomedical engineering, information security, and finance. Use staged implementation with simulation, proctored cases, competency assessment, and outcome monitoring. Prioritize interoperability with imaging and hospital systems, transparent human oversight for AI functions, cybersecurity controls, and maintenance planning. Evidence programs should evaluate radiation exposure, procedure duration, technical success, complications, training requirements, staff experience, and patient-relevant outcomes without relying on unsupported commercial claims.

Research Methodology for the Executive Assessment

This executive assessment uses a structured qualitative synthesis of the supplied market scope and established healthcare-technology considerations relevant to robotic-assisted PCI. The analysis organizes findings across technology, clinical workflow, regulation, infrastructure, workforce, data governance, and geography. Regional, group, and country comparisons are framed as system-level observations rather than quantitative rankings. No market estimates, shares, forecasts, or company-specific claims are presented; conclusions should be validated against peer-reviewed studies, clinical registries, regulatory documents, reimbursement policies, and institution-level implementation data.

Conclusion: Building Evidence-Based, Connected PCI Systems

Robotic-assisted PCI is best understood as part of a broader transformation toward digitally connected, data-supported interventional care. Its durable contribution will depend less on automation alone than on validated clinical utility, safe human-machine collaboration, interoperable infrastructure, and equitable access to training and expertise. Organizations that combine disciplined evaluation with responsible AI governance and practical workflow design will be better positioned to determine where robotic assistance improves care and where conventional approaches remain appropriate.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Robotic Assisted Percutaneous Coronary Intervention Market, by System Type

• 7.1. Introduction
• 7.2. Fully Automated Systems
• 7.3. Hybrid Systems
• 7.4. Teleoperated Systems

8. Robotic Assisted Percutaneous Coronary Intervention Market, by Procedure Type

• 8.1. Introduction
• 8.2. Complex PCI
• 8.3. Simple PCI

9. Robotic Assisted Percutaneous Coronary Intervention Market, by Component

• 9.1. Introduction
• 9.2. Disposable Accessories
• 9.3. Robotic Systems
• 9.4. Software

10. Robotic Assisted Percutaneous Coronary Intervention Market, by End User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Clinics
• 10.4. Hospitals

11. Robotic Assisted Percutaneous Coronary Intervention Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. Robotic Assisted Percutaneous Coronary Intervention Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. Robotic Assisted Percutaneous Coronary Intervention Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Biosensors International Group Ltd
• 15.2. BIOTRONIK SE & Co. KG
• 15.3. Boston Scientific Corporation
• 15.4. CathWorks Ltd
• 15.5. EP Solutions SA
• 15.6. Hansen Medical Inc
• 15.7. Intuitive Surgical Inc
• 15.8. Medical Microinstruments Inc
• 15.9. Medtronic plc
• 15.10. Meril Life Sciences Pvt Ltd
• 15.11. Microbot Medical Inc.
• 15.12. MicroPort Inc
• 15.13. NDR Medical Technology AG
• 15.14. OrbusNeich Medical Group Holdings Limited
• 15.15. Perfint Healthcare Pvt Ltd
• 15.16. Robocath SA
• 15.17. Siemens Healthineers AG
• 15.18. Stereotaxis, Inc.
• 15.19. Stryker Corporation
• 15.20. Think Surgical Inc
• 15.21. XCath Inc.

16. Key Experts